ClinicalTrials.Veeva

Menu

Effectiveness of Human Rotavirus Vaccine, Rotarix™ Against Rotavirus Severe Gastroenteritis (RV SGE) in Infants

GlaxoSmithKline (GSK) logo

GlaxoSmithKline (GSK)

Status

Completed

Conditions

Rotavirus Severe Gastroenteritis

Treatments

Other: Collection of information
Procedure: Collection of stool samples

Study type

Observational

Funder types

Industry

Identifiers

Details and patient eligibility

About

This study aims to evaluate the effectiveness of Rotarix™ vaccine in the general population in Singapore by monitoring the overall reduction in RV SGE and also by assessing the direct protection offered by the vaccine in hospitalised infants through a case-control study.

Full description

This Protocol Posting has been updated following an amendment of the Protocol.

Enrollment

1,270 patients

Sex

All

Ages

Under 5 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Inclusion criteria for surveillance subjects

  • A male or female child aged < 60 months at the time of admission (a child becomes ineligible on the day of its fifth birthday).
  • Subject admitted with acute GE as an inpatient to the study site during the study period.
  • Written informed consent obtained from the parent or guardian of the subject. Selection criteria for cases

Cases will be limited to those surveillance subjects:

  • who are born after 1 November 2005 (date of availability of Rotarix™ vaccination in Singapore),
  • who are aged at least 16 weeks at the time of hospital admission.
  • whose stool samples are tested positive for RV. Selection criteria for controls

All controls must satisfy the following criteria at study entry:

  • Admitted for acute disease with non-GE causes in the same hospital as the case , with the closest admission date to the cases.
  • Aged at least 16 weeks at the time of hospital admission.
  • Born within a range of ± 2 weeks from the date of birth of cases. In case there is no suitable match, then the range would be extended to ± 4 weeks.
  • Written informed consent obtained from the subject's parents/guardians.

Exclusion criteria

For enrolment of surveillance subjects

The following criteria should be checked at the time of study entry. If any apply, the subject must not be included in the study:

  • The diagnoses at admission to the study site do not include acute GE.
  • Children for whom stool samples are not available up to 48 hours after admission.
  • The onset of GE is after 48 hours of admission to the hospital (i.e. nosocomial GE).
  • Children with a history of chronic and genetic diseases. For selection of cases

In addition to the exclusion criteria for surveillance subjects, cases will not be selected if the following criterion applies:

  • Subjects who had a previous episode of acute GE less than a week back i.e. recurrent GE episode.
  • Subjects who have been already enrolled in the study.
  • Subjects whose vaccination history could not be ascertained. For selection of controls

The following criteria should be checked at the time of study entry. If any apply, the controls must not be included in the study:

  • Child who has symptoms of GE on the day of interview of his/her parent or guardian or had an episode of GE within 14 days prior to the day of interview.
  • Child who has been already enrolled in the study as case or control.
  • The onset of GE occurs after admission at the hospital.
  • Child whose vaccination history could not be ascertained.

Trial design

1,270 participants in 2 patient groups

Group A
Description:
Cases
Treatment:
Other: Collection of information
Procedure: Collection of stool samples
Group B
Description:
Controls
Treatment:
Other: Collection of information

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems